ArticleScientific reports2026
A novel bicistronic vector inducing balanced alternative splicing for antibody production.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Efficient and stable production of recombinant monoclonal antibodies requires sufficient expression of light (LC) and heavy (HC) chains within host cells. Conventional bicistronic systems such as internal ribosome entry site (IRES)- or 2 A peptide-based vectors often suffer from imbalanced translation efficiencies or the presence of residual peptide tags that can compromise antibody quality. We developed a novel bicistronic expression platform, designated the cassette exon-associated (CAE) system, which exploits alternative splicing derived from the HEG1 gene to generate two mRNA isoforms from a single promoter. The CAE cassette contains synthetic splice donor and acceptor sequences that enable expression of LC and HC without additional peptide sequences. The optimized construct, pCAE3.31, driven by various promoters-including chicken β-actin, cytomegalovirus, and human elongation factor-1α-efficiently expressed functional antibodies in multiple mammalian cell lines. Compared with IRES-based systems, the CAE vector achieved an 8-fold higher antibody yield. Fab fragments were also produced using the CAE system. The CAE system represents a compact and versatile bicistronic expression strategy that ensures expression of LC and HC, avoids extraneous peptide fusion, and is compatible with major mammalian promoters. This platform facilitates efficient production of recombinant antibodies and Fab fragments, supporting screening and potential therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.